ePrints

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach

Lookup NU author(s): Dr Paul Brennan, Dr Ahmed Elsharkawy, Professor Derek Mann

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2023, Springer Nature Limited. Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only histological predictor of liver-related morbidity and mortality in NASH identified to date. Moreover, fibrosis regression is associated with improved clinical outcomes. However, despite numerous clinical trials of plausible drug candidates, an approved antifibrotic therapy remains elusive. Increased understanding of NASH susceptibility and pathogenesis, emerging human multiomics profiling, integration of electronic health record data and modern pharmacology techniques hold enormous promise in delivering a paradigm shift in antifibrotic drug development in NASH. There is a strong rationale for drug combinations to boost efficacy, and precision medicine strategies targeting key genetic modifiers of NASH are emerging. In this Perspective, we discuss why antifibrotic effects observed in NASH pharmacotherapy trials have been underwhelming and outline potential approaches to improve the likelihood of future clinical success.

Publication metadata

Author(s): Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield JA

Publication type: Review

Publication status: Published

Journal: Nature Reviews Gastroenterology and Hepatology

Year: 2023

Volume: 20

Pages: 679–688

Online publication date: 02/06/2023

Acceptance date: 09/05/2023

ISSN (print): 1759-5045

ISSN (electronic): 1759-5053

Publisher: Nature Research

URL: https://doi.org/10.1038/s41575-023-00796-x

DOI: 10.1038/s41575-023-00796-x

Share